Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q3 2022 · 10-Q
Revenue$17.06M$17.06M−1.4% vs Q3 2021 Net Income-$985.00K-$985.00KN/M vs Q3 2021 EPS Diluted-$0.01-$0.01N/M vs Q3 2021 Gross Profit$10,207,000−3.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flowderived-$3,740,000N/M Margins · derivedGross margin59.8%−1.3 pt vs Q3 2021
Operating margin-18.0%+33.1 pt vs Q3 2021
Net margin-5.8%+45.4 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 2, 2022 · 33 d after period end